EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pan-cancer proteogenomics expands the landscape of therapeutic targets

Sara R Savage, Xinpei Yi, Jonathan T Lei, Bo Wen, Hongwei Zhao, Yuxing Liao, Eric J Jaehnig, Lauren K Somes, Paul W Shafer, Tobie D Lee, Zile Fu, Yongchao Dou und 5 weitere

Cell · 2024-08 · 187 (16) · 4389-4407.e15

DOI: 10.1016/j.cell.2024.05.039 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell, 2024-08. Verfasst von Sara R Savage und 16 weiteren Autor:innen. Beteiligte Einrichtung: Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA; Department of Molecular and Human Genetics, Baylor College of…. Hauptthemen laut MEDLINE: Proteogenomics, Neoplasms. Die Arbeit wurde bisher 142-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fewer than 200 proteins are targeted by cancer drugs approved by the Food and Drug Administration (FDA). We integrate Clinical Proteomic Tumor Analysis Consortium (CPTAC) proteogenomics data from 1,043 patients across 10 cancer types with additional public datasets to identify potential therapeutic targets. Pan-cancer analysis of 2,863 druggable proteins reveals a wide abundance range and identifies biological factors that affect mRNA-protein correlation. Integration of proteomic data from tumors and genetic screen data from cell lines identifies protein overexpression- or hyperactivation-driven druggable dependencies, enabling accurate predictions of effective drug targets. Proteogenomic identification of synthetic lethality provides a strategy to target tumor suppressor gene loss. Combining proteogenomic analysis and MHC binding prediction prioritizes mutant KRAS peptides as promising public neoantigens. Computational identification of shared tumor-associated antigens followed by experimental confirmation nominates peptides as immunotherapy targets. These analyses, summarized at https://targets.linkedomics.org, form a comprehensive landscape of protein and peptide targets for companion diagnostics, drug repurposing, and therapy development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProteogenomicsNeoplasmsHumansMolecular Targeted TherapyImmunotherapyAntigens, NeoplasmCell Line, TumorAntineoplastic AgentsPeptidesProteomicsProto-Oncogene Proteins p21(ras)

Stichwörter der Autor:innen

pan-cancer, proteogenomics, drug targets, proteomics, synthetic lethality, neoa…

Substanzen

Antigens, NeoplasmAntineoplastic AgentsPeptidesProto-Oncogene Proteins p21(ras)

Autor:innen und Institutionen

  • Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.
  • Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital and Key Laboratory of Carcinogenesis and Cancer Invasion of the Ministry of China, Fudan University, 180 Fenglin Road, Shanghai…
  • Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA.
  • Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA.
  • Key Laboratory of Multi-Cell Systems, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai 200031, China.
  • Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA.

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS
  • National Natural Science Foundation of China
  • National Cancer Institute
  • AstraZeneca
  • Cancer Prevention and Research Institute of Texas
  • National Institutes of Health

Zitieren

APA

Savage, S. R., Yi, X., Lei, J. T., Wen, B., Zhao, H., Liao, Y., Jaehnig, E. J., Somes, L. K., Shafer, P. W., Lee, T. D., Fu, Z., Dou, Y., Shi, Z., Gao, D., Hoyos, V., Gao, Q., & Zhang, B. (2024). Pan-cancer proteogenomics expands the landscape of therapeutic targets. Cell, 187(16), 4389-4407.e15. https://doi.org/10.1016/j.cell.2024.05.039

Vancouver

Savage SR, Yi X, Lei JT, Wen B, Zhao H, Liao Y, et al. Pan-cancer proteogenomics expands the landscape of therapeutic targets. Cell. 2024;187(16):4389-4407.e15. doi:10.1016/j.cell.2024.05.039

BibTeX
@article{Savage2024,
  author = {Savage, Sara R and Yi, Xinpei and Lei, Jonathan T and Wen, Bo and Zhao, Hongwei and Liao, Yuxing and Jaehnig, Eric J and Somes, Lauren K and Shafer, Paul W and Lee, Tobie D and Fu, Zile and Dou, Yongchao and Shi, Zhiao and Gao, Daming and Hoyos, Valentina and Gao, Qiang and Zhang, Bing},
  title = {Pan-cancer proteogenomics expands the landscape of therapeutic targets},
  journal = {Cell},
  year = {2024},
  volume = {187},
  number = {16},
  pages = {4389--4407.e15},
  doi = {10.1016/j.cell.2024.05.039}
}
Kostenlos starten →